In order to analyze whether baseline CEA serum levels simply reflect high tumor load, resulting in detrimental treatment outcome, a separate cohort of 129 patients who received cetuximab-based chemotherapy was analyzed. This evidence concerns the gene CEACAM5 and neoplasm.